Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2022-11-17 Share Issue/Capital Cha…
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Zealand Pharma regarding an increase in share capital resulting from the exercise of employee warrants. This falls under the category of share capital changes or new share issues. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the correct classification for announcements regarding new share issues or capital changes.
2022-11-17 Danish
Director's Dealing 2022
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a 'Sale of Shares' transaction by a Board of Directors member (Louise Gjelstrup) of Zealand Pharma A/S on November 15, 2022. This perfectly matches the definition of Director's Dealing (insider trades by executives/directors), which corresponds to the filing code DIRS.
2022-11-17 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard regulatory template for the notification of transactions by persons discharging managerial responsibilities (PDMRs). It explicitly lists the name of the director (Leonard Kruimer), the nature of the transaction (Sale of Shares), the volume, price, and the date of the transaction. This is a classic 'Director's Dealing' notification.
2022-11-17 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It explicitly identifies a member of the Board of Directors (Frederik Barfoed Beck) and details a sale of shares. This is a classic insider trading disclosure, which corresponds to the 'Director's Dealing' category.
2022-11-17 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is a standard notification form for transactions by persons discharging managerial responsibilities (PDMRs), specifically detailing a sale of shares by a member of the Board of Directors of Zealand Pharma A/S. This matches the definition for 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2022-11-17 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document follows the standard template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMR). It explicitly lists the name of the director (Michael J. Owen), the nature of the transaction (Sale of Shares), the price, volume, and the date of the transaction. This is a classic insider trading disclosure, which falls under the 'Director's Dealing' category.
2022-11-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.